New CAH drug shows promise in Long-Term safety trial
Disease control
Completed
This study looked at the long-term safety of a drug called Chronocort for people aged 16 and older with congenital adrenal hyperplasia (CAH). Researchers monitored 76 participants for signs of over- or under-treatment, adrenal crises, and side effects. The goal was to see if Chro…
Phase: PHASE3 • Sponsor: Neurocrine UK Limited • Aim: Disease control
Last updated May 26, 2026 12:06 UTC